

Soeren Mattke

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9415501/publications.pdf>

Version: 2024-02-01

71
papers

4,468
citations

361413
20
h-index

114465
63
g-index

74
all docs

74
docs citations

74
times ranked

4812
citing authors

#	ARTICLE	IF	CITATIONS
1	Nurse-Staffing Levels and the Quality of Care in Hospitals. New England Journal of Medicine, 2002, 346, 1715-1722.	27.0	1,879
2	Systematic Review: The Evidence That Publishing Patient Care Performance Data Improves Quality of Care. Annals of Internal Medicine, 2008, 148, 111.	3.9	726
3	Utilization of Anesthesia Services During Outpatient Endoscopies and Colonoscopies and Associated Spending in 2003-2009. JAMA - Journal of the American Medical Association, 2012, 307, 1178.	7.4	174
4	Anaplastic Large Cell Lymphoma and Breast Implants: A Systematic Review. Plastic and Reconstructive Surgery, 2011, 127, 2141-2150.	1.4	167
5	A review of methods to measure health-related productivity loss. American Journal of Managed Care, 2007, 13, 211-7.	1.1	166
6	Evidence for the effect of disease management: is \$1 billion a year a good investment?. American Journal of Managed Care, 2007, 13, 670-6.	1.1	127
7	Rigorous Development does not Ensure that Guidelines are Acceptable to a Panel of Knowledgeable Providers. Journal of General Internal Medicine, 2008, 23, 37-44.	2.6	98
8	Breast Implantâ€“Associated Anaplastic Large Cell Lymphoma. Plastic and Reconstructive Surgery, 2015, 135, 713-720.	1.4	91
9	Untangling Practice Redesign from Disease Management: How Do We Best Care for the Chronically Ill?. Annual Review of Public Health, 2009, 30, 385-408.	17.4	89
10	Anaplastic Large Cell Lymphoma and Breast Implants. Plastic and Reconstructive Surgery, 2011, 128, 629-639.	1.4	89
11	Systematic review of the impact of worksite wellness programs. American Journal of Managed Care, 2012, 18, e68-81.	1.1	84
12	Chronic Stroke Outcome Measures for Motor Function Intervention Trials. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, S163-9.	2.2	81
13	The curse of wealth â€“ Middle Eastern countries need to address the rapidly rising burden of diabetes. International Journal of Health Policy and Management, 2014, 2, 109-114.	0.9	69
14	Breast Implantâ€“associated Anaplastic Large Cell Lymphoma. Plastic and Reconstructive Surgery - Global Open, 2015, 3, e296.	0.6	57
15	Assessing the Preparedness of the U.S. Health Care System Infrastructure for an Alzheimer's Treatment. , 2017, , .		51
16	Application of patient safety indicators internationally: a pilot study among seven countries. International Journal for Quality in Health Care, 2009, 21, 272-278.	1.8	43
17	The Role of Antipsychotic Plasma Levels in the Treatment of Schizophrenia. American Journal of Psychiatry, 2017, 174, 421-426.	7.2	30
18	Development of a Model to Predict Healing of Chronic Wounds Within 12 Weeks. Advances in Wound Care, 2020, 9, 516-524.	5.1	29

#	ARTICLE	IF	CITATIONS
19	Bloodâ€based biomarkers for Alzheimer's pathology and the diagnostic process for a diseaseâ€modifying treatment: Projecting the impact on the cost and wait times. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12081.	2.4	28
20	Measuring Hospital Quality: Can Medicare Data Substitute for All-Payer Data?. Health Services Research, 2003, 38, 1487-1508.	2.0	24
21	Who Gets Disease Management?. Journal of General Internal Medicine, 2009, 24, 649-655.	2.6	22
22	Expected wait times for access to a diseaseâ€modifying Alzheimer's treatment in the United States. Alzheimer's and Dementia, 2022, 18, 1071-1074.	0.8	21
23	Nurse Staffing and Quality of Care in Hospitals in the United States. Policy, Politics, and Nursing Practice, 2002, 3, 306-308.	1.8	18
24	Understanding the Relationship between Incentive Design and Participation in U.S. Workplace Wellness Programs. American Journal of Health Promotion, 2016, 30, 198-203.	1.7	17
25	Effect of an Employer-Sponsored Health and Wellness Program on Medical Cost and Utilization. Population Health Management, 2013, 16, 1-6.	1.7	16
26	The Potential Emergence of Disease-Modifying Treatments for Alzheimer Disease: The Role of Primary Care in Managing the Patient Journey. Journal of the American Board of Family Medicine, 2019, 32, 931-940.	1.5	16
27	Assessing the Preparedness of the Health Care System Infrastructure in Six European Countries for an Alzheimer's Treatment. Rand Health Quarterly, 2019, 8, 2.	0.5	16
28	Improving Antipsychotic Adherence Among Patients With Schizophrenia: Savings for States. Psychiatric Services, 2015, 66, 343-345.	2.0	15
29	Effect of Disease Management on Prescription Drug Treatment: What Is The Right Quality Measure?. Disease Management: DM, 2007, 10, 91-100.	1.0	14
30	Projecting the longâ€term societal value of a diseaseâ€modifying treatment for Alzheimer's disease in the United States. Alzheimer's and Dementia, 2022, 18, 142-151.	0.8	14
31	Incentives, Program Configuration, and Employee Uptake of Workplace Wellness Programs. Journal of Occupational and Environmental Medicine, 2016, 58, 30-34.	1.7	13
32	Impact of 2 employer-sponsored population health management programs on medical care cost and utilization. American Journal of Managed Care, 2009, 15, 113-20.	1.1	13
33	Upcoding and Anesthesia Risk in Outpatient Gastrointestinal Endoscopy Procedures. JAMA Internal Medicine, 2016, 176, 855.	5.1	12
34	Cost-Effectiveness of Extended and One-Time Screening Versus No Screening for Non-Valvular Atrial Fibrillation in the USA. Applied Health Economics and Health Policy, 2020, 18, 533-545.	2.1	11
35	Association between state stay-at-home orders and risk reduction behaviors and mental distress amid the COVID-19 pandemic. Preventive Medicine, 2020, 141, 106299.	3.4	11
36	Assessing the Preparedness of the Canadian Health Care System Infrastructure for an Alzheimer's Treatment. , 2019, , .		11

#	ARTICLE	IF	CITATIONS
37	Potential Benefits to Patients and Payers From Increased Measurement of Antipsychotic Plasma Levels in the Management of Schizophrenia. <i>Psychiatric Services</i> , 2018, 69, 12-14.	2.0	10
38	Simulated long-term outcomes of early use of long-acting injectable antipsychotics in early schizophrenia. <i>Microbial Biotechnology</i> , 2019, 13, 1357-1365.	1.7	10
39	Adoption and use of stand-alone electronic prescribing in a health plan-sponsored initiative. <i>American Journal of Managed Care</i> , 2010, 16, 182-9.	1.1	10
40	Quality Measures Based on Presenting Signs and Symptoms of Patients. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 520.	7.4	8
41	Estimating minimal clinically important differences for two scales in patients with chronic traumatic brain injury. <i>Current Medical Research and Opinion</i> , 2020, 36, 1999-2007.	1.9	7
42	Medicare Coverage of Anesthesia Services During Screening Colonoscopies for Patients at Low Risk of Sedation-Related Complications. <i>JAMA Internal Medicine</i> , 2015, 175, 1848.	5.1	6
43	Projection of budgetary savings to US state Medicaid programs from reduced nursing home use due to an Alzheimer's disease treatment. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12159.	2.4	6
44	Outpatient Wound Clinics During COVID-19 Maintained Quality but Served Fewer Patients. <i>Journal of the American Medical Directors Association</i> , 2022, 23, 660-665.e5.	2.5	5
45	Anesthesia Service Use and the Uptake of Screening Colonoscopies. <i>Medical Care</i> , 2017, 55, 623-628.	2.4	4
46	Health Economic Evaluation of an Ultrathin, Bioresorbable-Polymer Sirolimus-Eluting Coronary Stent Compared to a Thin, Durable-Polymer Everolimus-Eluting Stent. <i>Cardiovascular Revascularization Medicine</i> , 2019, 20, 752-757.	0.8	4
47	Temporal Trends in Mortality after Transcatheter Aortic Valve Replacement: A Systematic Review and Meta-Regression Analysis. <i>Structural Heart</i> , 2020, 4, 16-23.	0.6	4
48	The Potential Benefits of Deferred Payment for a Hypothetical Gene Therapy for Congestive Heart Failure: A Cost-Consequence Analysis. <i>Applied Health Economics and Health Policy</i> , 2020, 18, 669-677.	2.1	4
49	Determining minimally clinically important differences for outcome measures in patients with chronic motor deficits secondary to traumatic brain injury. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 1051-1058.	2.8	4
50	Financial Incentives: Only One Piece of the Workplace Wellness Puzzle Comment on "Corporate Wellness Programs: Implementation Challenges in the Modern American Workplace". <i>International Journal of Health Policy and Management</i> , 2013, 1, 311-312.	0.9	4
51	Does Targeting Higher Health Risk Employees or Increasing Intervention Intensity Yield Savings in a Workplace Wellness Program?. <i>Journal of Occupational and Environmental Medicine</i> , 2015, 57, 1257-1261.	1.7	3
52	Comment on "Do Workplace Health Promotion (Wellness) Programs Work?". <i>Journal of Occupational and Environmental Medicine</i> , 2015, 57, e9.	1.7	3
53	Impact of Event Severity on Hospital Rankings Based on Heart Failure Readmission Rates. <i>Population Health Management</i> , 2019, 22, 243-247.	1.7	3
54	Is Korea Prepared for an Alzheimer's Disease-Modifying Therapy? Assessing the Korean Healthcare System Infrastructure and the Effect of Blood-Based Biomarker Tests. <i>Annals of Geriatric Medicine and Research</i> , 2021, 25, 33-38.	1.8	3

#	ARTICLE	IF	CITATIONS
55	Memory care approaches to better leverage capacity of dementia specialists: a narrative synthesis. <i>Neurodegenerative Disease Management</i> , 2021, 11, 239-250.	2.2	3
56	How Much Value Would a Treatment for Alzheimer's Disease Offer? Cost-Effectiveness Thresholds for Pricing a Disease-Modifying Therapy. <i>Current Alzheimer Research</i> , 2021, 17, 819-822.	1.4	3
57	Developing a pathway to support the appropriate, affordable, and widespread use of effective Alzheimer's prevention drugs. <i>Alzheimer's and Dementia</i> , 2022, 18, 7-9.	0.8	3
58	Association of wound healing with quality and continuity of care and sociodemographic characteristics. <i>American Journal of Managed Care</i> , 2022, 28, e146-e152.	1.1	3
59	Testing the DMAA's Recommendations for Disease Management Program Evaluation. <i>Population Health Management</i> , 2008, 11, 241-245.	1.7	2
60	Detection of Undiagnosed Disease in Medicare Beneficiaries After a Clinical Home Visit. <i>Population Health Management</i> , 2017, 20, 41-47.	1.7	2
61	Cost and Mortality Implications of Lower Event Rates After Implantation of an Ultrathin-Strut Coronary Stent Compared With a Thin-Strut Stent Over Four Years. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 835-842.	0.8	2
62	Voluntary partial capitation: the Community Nursing Organization Medicare demonstration. <i>Health Care Financing Review</i> , 2005, 26, 21-37.	1.8	2
63	Why would Canada have the longest wait times for an Alzheimer's treatment among the G7 countries? A policy analysis. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	2
64	Sterilization of Endoscopic Instruments. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 524.	7.4	1
65	From Trials to Practice: Are We Ready for a Disease-Modifying Treatment?. , 2022, , 343-353.		1
66	Comment on Steinberg et al. <i>Journal of Occupational and Environmental Medicine</i> , 2016, 58, e114.	1.7	0
67	TWO-YEAR RESULTS AFTER IMPLANTATION OF AN ULTRATHIN, BIORESORBABLE POLYMER SIROLIMUS-ELUTING CORONARY STENT COMPARED TO A THIN, DURABLE POLYMER EVEROLIMUS-ELUTING STENT: HEALTH ECONOMIC EVALUATION. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1152.	2.8	0
68	Impact of blood biomarkers on cost and wait time in diagnosing treatment-eligible patients for Alzheimer's disease: A simulation study. <i>Alzheimer's and Dementia</i> , 2020, 16, e037200.	0.8	0
69	How prepared are the EU's countries' health systems to deliver a disease-modifying treatment for Alzheimer's?. <i>Alzheimer's and Dementia</i> , 2020, 16, e037257.	0.8	0
70	Results from a national survey on chronic care management by health plans. <i>American Journal of Managed Care</i> , 2015, 21, 370-6.	1.1	0
71	Projection of net savings to U.S. state Medicaid programs from reduced nursing home utilization due to an Alzheimer's treatment. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0